Teva Pharmaceutical Industries Ltd. (TEVA)

17.82
NYSE : Health Technology
Prev Close 17.71
Day Low/High 17.72 / 17.99
52 Wk Low/High 10.85 / 33.82
Avg Volume 12.96M
Exchange NYSE
Shares Outstanding 1.02B
Market Cap 18.11B
EPS -16.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Mylan's Stock Gets Bump After Investor Day

Mylan's Stock Gets Bump After Investor Day

Following Wednesday's event, Leerink analyst Ami Fadia said she is 'incrementally more positive' on the drugmaker's pipeline and diversified business model and moved her rating to outperform.

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

As President Trump tees up a set of 25% tariffs on a wide range of products against China trade, generic drug makers as well as their patients likely will be affected.

Teva Analyst: Wall Street's Forecasts Look 'Overly Ambitious'

Teva Analyst: Wall Street's Forecasts Look 'Overly Ambitious'

RBC's Randall Stanicky says concerns have moved from being about global generic growth to Teva's branded drug business.

Teva Announces The Launch Of A Generic Version Of Lialda® In The United States

Teva Announces The Launch Of A Generic Version Of Lialda® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Lialda ®1 (mesalamine) delayed-release tablets, 1.

Teva Announces The Launch Of A Generic Version Of ALOXI® In The United States

Teva Announces The Launch Of A Generic Version Of ALOXI® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the launch of a generic version of ALOXI ®1 (palonosetron HCI) injection, 0.

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis subsidiary Sandoz Canada will work with cannabis producer Tilray to produce non-smokable medical cannabis products in Canada, becoming the first Big Pharma company to get into medical pot.

Trump Opioid Policy Rollout Includes Call for Death Penalty for Dealers

Trump Opioid Policy Rollout Includes Call for Death Penalty for Dealers

President Trump made a long-awaited announcement of his administration's opioid plan in a New Hampshire speech that was part policy roll out and part political rally.

Teva To Present At The Cowen & Company 38th Annual Healthcare Conference

Teva To Present At The Cowen & Company 38th Annual Healthcare Conference

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Cowen & Company 38 th Annual Healthcare Conference in Boston, MA.

Generic Drug Sector Shifting With Legal Pressure, Changes at FDA

Generic Drug Sector Shifting With Legal Pressure, Changes at FDA

A massive price-fixing lawsuit brought by 45 states against a group of generic drug producers as well as a changing of the guard at the Food and Drug Administration may lead to changes in the generic drug sector.

Teva Announces Upsizing And Successful Pricing Of $4.5 Billion Of Senior Notes

Teva Announces Upsizing And Successful Pricing Of $4.5 Billion Of Senior Notes

Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) ("Teva") announced today that it successfully priced the offering of $4.

Study: Over-the-Counter Meds More Effective For Chronic Back Pain Than Opioids

Study: Over-the-Counter Meds More Effective For Chronic Back Pain Than Opioids

A study published by the Journal of the American Medical Association shows OTC drugs were more effective in cutting pain for chronic back pain and osteoarthritis hip and knee patients than opioids.

Mylan Breaks Out Amid Generic Malaise; Target Shorts Rejoice -- ICYMI

Mylan Breaks Out Amid Generic Malaise; Target Shorts Rejoice -- ICYMI

Here's what you need to know now for Tuesday, March 6.

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.

4 Smart Money Stock Picks

4 Smart Money Stock Picks

Sometimes finding fresh investing inspiration can be a challenge, but if you examine the latest hedge fund moves, you can find insights from some of the world's savviest investors.

Teva Announces Launch Of Offering Of Senior Notes

Teva Announces Launch Of Offering Of Senior Notes

Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) ("Teva") announced today that its special purpose finance subsidiary, (i) Teva Pharmaceutical Finance Netherlands II B.

Attorney General Sessions Announces New Federal Opioids Taskforce

Attorney General Sessions Announces New Federal Opioids Taskforce

After months of inaction by the federal government on the crisis regarding opioid abuse, Attorney General Jeff Sessions announced the creation of a task force charged with looking at how drug makers and distributors operate.

Allergan Handed Patent Defeat Over Restasis

Allergan Handed Patent Defeat Over Restasis

Allergan's losing streak in a bid to stash patent rights protecting cash cow Restasis remains intact as the U.S. Patent Trial and Appeal Board rejects a move to dismiss a challenge brought by a trio of pharma companies.

Jim Cramer: The Government Should Admit It Goofed With These Crazy Instruments

Jim Cramer: The Government Should Admit It Goofed With These Crazy Instruments

We used to think of what's in the public's interest when it comes to securities.

Teva Announces Exclusive Launch Of Two Strengths Of A Generic Version Of Solodyn® In The United States

Teva Announces Exclusive Launch Of Two Strengths Of A Generic Version Of Solodyn® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the exclusive launch of two strengths of a generic version of Solodyn ®1 (minocycline HCl) Extended Release Tablets, 65 and 115 mg, in the U.

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

The Swiss pharmaceutical firm's U.S. generic pill business could attract as much as $1.6 billion, Reuters reported.

Five-Day Winning Streak in Stocks Expected to Continue

Five-Day Winning Streak in Stocks Expected to Continue

On Thursday alone, we experience both free-fall, as well as a raucous rally.

Dow Jumps Over 300 Points, Posting Its Fifth Straight Day of Gains

Dow Jumps Over 300 Points, Posting Its Fifth Straight Day of Gains

The Dow, S&P 500 and Nasdaq all finish higher on Thursday.

Stock Markets Around the World Are Soaring Again

Stock Markets Around the World Are Soaring Again

Japanese, Hong Kong and European markets continue Wednesday's Wall Street rally.

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments

We used to think of what's in the public's interest when it comes to securities.

GM, Teva, Facebook and Other New Jana Partners Positions

GM, Teva, Facebook and Other New Jana Partners Positions

The insurgent manager that helped engineer the Amazon-Whole Foods combination just offered up a window into his latest allocations, any of which could soon become campaigns. Both Jana Partners and Warren Buffett's Berkshire Hathaway Inc. reported new positions in Teva

Teva Shares Pop After-Hours on News of Berkshire Investment

Teva Shares Pop After-Hours on News of Berkshire Investment

Berkshire Hathaway purchased 18.9 million shares of the drugmaker, according to its 13F filing.

Clearly, Warren Buffett Loves Apple's Stock

Clearly, Warren Buffett Loves Apple's Stock

Warren Buffett continues to eat up Apple's stock. He also has bought a stake in struggling generics drug maker Teva.

TheStreet Quant Rating: D+ (Sell)